NeoGenomics to appeal preliminary injunction by North Carolina court

NeoGenomics announced that NeoGenomics Laboratories, Inc., a subsidiary of NeoGenomics Inc., will appeal the preliminary injunction issued by the United States District Court for the Middle District of North Carolina. The initial determination is that Natera, Inc. demonstrated a likelihood that products using RaDaR technology infringe one Natera, Inc. patent. The order specifically allows patients already using RaDaR to continue their use. In addition, the order explicitly allows research projects and studies that are in progress, as well as clinical trials that are in progress or have been approved, to continue. In response to the court’s ruling, Chris Smith, CEO of NeoGenomics said, “We continue to believe in RaDaR’s innovative and distinguished technology and plan to appeal the Court’s ruling and defend our technology. We remain committed to bringing our highly sensitive test to market and providing cancer patients and their clinicians with options for their care.”